Latest Market News

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Ampol Limited reports a robust fourth quarter Lytton Refiner Margin of US$15.14 per barrel, underpinning a strong preliminary FY25 earnings update with an expected EBIT of approximately $945 million.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Coronado Global Resources reported a solid FY25 with increased saleable production and reduced mining costs, underpinned by key expansions and refinancing deals that set the stage for stronger cash flow in 2026.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

Beforepay Group reported a 17% rise in advances and an 18% increase in revenue for Q2 FY26, while profit fell sharply due to holiday-season defaults and strategic investments.

The Australian Wealth Advisors Group has launched a profitable joint venture with CHN Partners, leveraging an established accounting practice to boost its wealth management footprint.

Gratifii Limited has reported its highest quarterly cash receipts to date, alongside progressing key acquisitions and completing a major client platform migration.

Clever Culture Systems has expanded its APAS Independence installed base to 27 instruments globally and surpassed $1 million in annual recurring revenue, underpinned by strong sales momentum and customer validation.

Nanoveu Limited has marked significant progress in its 16nm ECS-DoT edge-AI system-on-chip development, secured a strategic $7.5 million capital raise, and earned top honours at CES 2026, positioning itself for commercial breakthroughs in 2026.